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Muscle regulates mTOR dependent axonal
local translation in motor neurons via
CTRP3 secretion: implications for a
neuromuscular disorder, spinal muscular
atrophy
Wiebke A. Rehorst1, Maximilian P. Thelen1, Hendrik Nolte2, Clara Türk2, Sebahattin Cirak3,4, Jonathan M. Peterson5,
G. William Wong6, Brunhilde Wirth1,4,7,8, Marcus Krüger2, Dominic Winter9 and Min Jeong Kye1*

Abstract
Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder, which causes dysfunction/loss of lower
motor neurons and muscle weakness as well as atrophy. While SMA is primarily considered as a motor neuron
disease, recent data suggests that survival motor neuron (SMN) deficiency in muscle causes intrinsic defects. We
systematically profiled secreted proteins from control and SMN deficient muscle cells with two combined metabolic
labeling methods and mass spectrometry. From the screening, we found lower levels of C1q/TNF-related protein 3
(CTRP3) in the SMA muscle secretome and confirmed that CTRP3 levels are indeed reduced in muscle tissues and
serum of an SMA mouse model. We identified that CTRP3 regulates neuronal protein synthesis including SMN via
mTOR pathway. Furthermore, CTRP3 enhances axonal outgrowth and protein synthesis rate, which are well-known
impaired processes in SMA motor neurons. Our data revealed a new molecular mechanism by which muscles
regulate the physiology of motor neurons via secreted molecules. Dysregulation of this mechanism contributes to
the pathophysiology of SMA.
Keywords: Spinal muscular atrophy, SMN (survival motor neuron), Muscle secretome, Neuronal protein synthesis,
CTRP3, Motor neuron disease

Introduction
Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder with an incidence of 1 per 6000–10,
000 newborns [66, 72]. While the severity of SMA varies,
characteristic phenotypes of SMA patients include
muscle weakness and atrophy, defects in neuromuscular
junctions (NMJs) and motor neuron loss. In more than
95% of cases, SMA is caused by loss or mutations of the
SMN1 (Survival of Motor Neuron 1) gene. In addition to
SMN1, the human genome contains a copy gene SMN2,
which produces approximately 10% of SMN protein
compared to SMN1 due to a point mutation in exon7
* Correspondence: Min.kye@uk-koeln.de
1
Institute of Human Genetics, University of Cologne, Kerpener Str. 34, 50931
Cologne, Germany
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[40, 45]. As the severity of SMA is highly correlated with
SMN protein levels, the presence of additional SMN2
genes determines the severity of the disease [22, 41].
Rarely, SMN independent genetic modifiers are reported
as influencing factors for the severity of SMA [18, 29,
55, 60]. Primarily, SMA is considered as a motor neuron
disease with severe defects in NMJs and motor neurons,
leading to muscle wasting. However, growing amount of
evidence indicates that the severe type I SMA cases, with
one or two copies of SMN2, show multi-organ defects
[25]. Only in the milder cases of SMA, with 3–6 copies
of SMN2, are pathological symptoms restricted to motor
neurons, NMJs and muscles [75]. Nevertheless, it is not
clear whether moderate defects in other organs contribute to the fitness of NMJs and motor neurons even in
the mild forms of SMA.
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The NMJ is the synapse between motor neuron axons
and muscle fibers. As it plays a critical role in muscle
function, even minor dysfunction of the NMJ can cause
devastating outcomes such as muscle weakness and
atrophy [68]. At mature NMJs presynaptic motor neuron
axon terminals release acetylcholine to induce muscle
contraction by binding to acetylcholine receptors, which
form clusters at postsynaptic muscle fibers to potentiate
the responsiveness. While most NMJs stay remarkably
stable during adulthood in animals, the mature NMJs also
require dynamic denervation and re-innervation processes
to maintain their structure and functionality. For example,
it is known that muscle fibers release chemotactic signals
for motor axons to re-innervate during this process [24].
Dysfunction and degeneration of NMJs due to genetic or
other pathological reasons cause neuromuscular diseases.
At the presynaptic site, it may cause motor neuron loss
via dying-back mechanisms, and at the post-synaptic
muscle site, it causes muscle weakness and atrophy. In
case of a severe SMA mouse model, NMJ dysfunction was
observed in 4 days after birth, whereas motor neuron loss
was found in 14 days old mice [35]. While it is well
characterized how motor neurons regulate muscle function, it is less understood how muscles contribute to
neuronal physiology, especially in motor neuron diseases.
SMA motor neurons exhibit characteristic phenotypes.
In vitro, these phenotypes include impaired growth [61],
dysregulated splicing and miRNA processing [15, 23], reduced protein synthesis efficiency [1, 21, 37], impaired
energy metabolism [7, 47], enhanced excitability and impaired Ca2+ homeostasis together with mis-localized
Ca2+ channels [31]. Furthermore, well-described functions of SMN are the biogenesis of small nuclear ribonucleoproteins (snRNPs) [79] and trafficking of mRNAs to
axon terminals [1, 21]. Among these phenotypes of SMA
motor neurons, reduced protein synthesis efficiency may
contribute to impaired growth. Importantly, dysregulated protein synthesis has been also reported in other
neurological disorders such as Alzheimer’s disease,
Charcot-Marie-Tooth and Amyotrophic lateral sclerosis
[3, 34, 51]. These findings suggest that maintaining protein homeostasis is crucial for proper neuronal function.
While SMA motor neurons have been thoroughly investigated, the knowledge about SMA muscles and their
role in SMA pathology still remains elusive. It has been
reported that SMA muscle cells show intrinsic defects in
myogenic differentiation and energy metabolism [8, 9,
28] and that the proteome of skeletal muscles of
presymptomatic SMA mice is dysregulated prior neuronal degeneration [50]. However, whether or how defects in muscles influence motor neuron physiology, and
whether this contributes to SMA pathology is utterly
unknown. Here, we report that SMA muscle cells differentially secrete proteins and that this contributes to
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patho-phenotypes of SMA motor neurons. Furthermore,
we characterized the role of CTRP3, whose secretion
and expression were reduced in SMA muscles, in motor
neuron physiology.

Materials and methods
Animal model

Cells and tissues were isolated from an SMA mouse
model [30]. Heterozygous Smn KO mice (SmnKO/WT;
SMN20/0) and human SMN2 containing mice (SmnKO/KO;
SMN2tg/tg) in congenic FVB/N background were bred to
produce 50% of offspring as SMA mice (SmnKO/KO;
SMN2tg/0) and 50% phenotypically normal heterozygotes
(SmnKO/WT;SMN2tg/0) in each litter [59]. Wild type mice
were used as controls (Jackson). Animal care and all
additional procedures were performed according to the institutional animal care committee guidelines and the
German animal welfare laws and approved under the reference numbers 84–02.05.20.13.042, 84–02.04.2015.A378 and
UniKoeln_Anziege§4.16.020 and §4.17.025 of the LANUV
(Landesamt für Natur, Umwelt und Verbraucherschutz
NRW) state agency of North-Rhine-Westphalia.
Recombinant proteins and drugs

Full-length recombinant proteins were purchased from
Cusabio (mouse CTRP3: CSB-EP875360MO; human
CTRP3: CSB-EP883621HU) and MyBioSource (human
CTRP3: #MBS1265203). The water soluble mTOR inhibitor WYE-687 dihydrochloride was purchased from Tocris
Bioscience (#4282) and the protein synthesis inhibitor anisomycin was purchased from Sigma-Aldrich (#A9789).
Culture of cell lines and siRNA transfection

Muscle cell lines H-2Kb-tsA58, C2C12, and motor
neuron like cell line NSC-34 cells were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) with 10%
fetal calf serum (Biochrom) and penicillin/streptomycin
(Thermo Fisher Scientific). For proliferation, culture
medium of H-2Kb-tsA58 cells was further supplemented
with 0.5% chicken embryo extract (Seralab) and 0.02%
interferon γ (Roche) and cells were maintained at 33 °C
with 10% CO2. To differentiate H-2Kb-tsA58 cells, cells
were cultured in DMEM with 5% horse serum (Biochrom) at 37 °C. C2C12 cells were differentiated in
DMEM with 2% horse serum. For the differentiation of
NSC-34 cells, growth medium was supplemented by
50 μM retinoic acid (Sigma) for 3 days. The knockdown
of Smn in H-2Kb-tsA58 and C2C12 cells was performed
using siRNA (Smn #4390771 and negative control
#4390843 Silencer Select Pre-Designed siRNA,
Thermo Fisher Scientific) and Lipofectamine®2000 reagent (Thermo Fisher Scientific). Unless otherwise
stated, all cells were maintained at 37 °C in a humidified
incubator with 5% CO2.
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Primary motor neuron culture

Primary motor neurons were isolated from E13 embryos.
After spinal cords were dissociated in 1% Trypsin
(Worthington) with DNase I (Applichem) via triturating,
cells were seeded on poly-D-lysine (PDL, Sigma) coated
plates/coverslips with neuronal plating media (DMEM supplemented with 5% fetal calf serum (Biochrom), 0.6% glucose, penicillin/streptomycin (Thermo Fisher Scientific)
and amphotericin B (Promocell)). 25,000 cells/cm2 were
plated for imaging analyses and 145,000 cells/cm2 were
plated for protein analyses. On the following day, neuronal
plating media was replaced by motor neuron maintenance
medium (Neurobasal medium supplemented with B27 supplement (Thermo Fisher Scientific), 2 mM L-glutamine,
penicillin/streptomycin and amphotericin B with additional
growth factors: ciliary neurotrophic factor (CNTF, 10 ng/
ml, PeproTech), brain derived neurotrophic factor (BDNF,
10 ng/ml, PeproTech) and glia cell line derived neurotrophic factor (GDNF, 10 ng/ml, PeproTech). One-half of
media was changed every 3rd day, and cytosine arabinoside
(AraC) was added at 3DIV to a final concentration of 1 μM.
RNA isolation, cDNA synthesis and real-time PCR

Total RNA was extracted from motor neurons using the
mirVana™ miRNA Isolation Kit (Thermo Fisher Scientific).
We followed the manufacturer’s instructions. RNA
concentration was determined using the NanoDrop ND1000 spectrophotometer (Peqlab). cDNA was produced
from total RNA using the High-Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Scientific) with random
primers. mRNA expression was determined by real-time
PCR with PowerSYBR® Green PCR Master Mix (Thermo
Fisher Scientific) and 1 μM of gene specific primers. The
amplification conditions for Actb were: an initial incubation stage at 50 °C for 2 min, denaturation at 95 °C for 10
min and 40 cycles of amplification step (95 °C for 15 s,
60 °C for 30 s, and 72 °C for 40 s). The same conditions
were used for the amplification of the other genes, except
of different annealing temperatures (Ctrp3: 65 °C, Smn:
58 °C, SMN2: 59 °C, Vegf: 65 °C). An additional dissociation step was added to confirm the amplified product,
and the PCR product was always confirmed by Sanger
sequencing. Real-time PCR was performed with 7500
Real-Time PCR System (Thermo Fisher Scientific).
Sequences of gene specific primers are listed in
Additional file 1: Table S1.
Protein isolation from cells, tissues, organs and blood
plasma, and Western blot analysis

For plasma, tissue and organ isolation, P7 mice were
sacrificed by decapitation and blood was collected from
the open throat using EDTA-treated capillary blood collection tubes (Sarstedt). Blood cells were eliminated by
centrifugation. Proteins of cultured cells, tissues and
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organs were extracted with RIPA buffer (Sigma) supplemented with protease and phosphatase inhibitors
(Thermo Fisher Scientific). Snap frozen tissues and
organs were homogenized using ceramic beads in a
Precellys24 device (Peqlab) and DNA was sheared by
sonication. Protein concentration was determined by
BCA assay (Thermo Fisher Scientific). Equal protein
amounts were confirmed by SDS–PAGE and Western
blot analysis with house-keeping proteins and/or
Ponceau staining. The information about antibodies are
listed in Additional file 1: Table S8. Signals were
detected with ChemiDoc XRS + System (BioRad), and
quantification of signals were performed using ImageLab
software (BioRad).
Proteomics of muscle cell proteomes and secretomes

To screen for differentially expressed and secreted proteins of control and SMN-deficient H-2Kb-tsA58 myotubes, we followed a previously published protocol with
some modifications [20]. In brief, cells were transfected
with siRNA and simultaneously, differentiation was induced in SILAC DMEM supplemented with azidohomoalanine (AHA) and stable isotopes of arginine and
lysine (control: 13C6-Arg, d4-Lys; SmnKD: 13C6 15N4-Arg,
13
C6 15N2-Lys). After 72 h, the Smn knockdown (KD) efficiency was verified by Western blot analysis, and cell
lysates/conditioned media of control and Smn KD myotubes were combined. The conditioned medium was
concentrated using 3 kDa cutoff filters (Millipore) and
newly synthesized proteins from cells and secretomes
(concentrated medium) were enriched using the ClickiT Protein Enrichment Kit (Thermo Fisher Scientific)
following the manufacturer’s protocol. Resin-bound proteins were reduced using 10 mM DTT, alkylated with 50
mM acrylamide, and finally digested with trypsin overnight at 37 °C. Peptide solutions were desalted using
Oasis HLB 1 cc Cartridges (Waters) and fractionated in
12 fractions by OFFGEL electrophoresis using 13 cm pI
3–10 strips (GE Healthcare) as described elsewhere [64].
Samples were purified using C18 STAGETips [58], dried
using a vacuum centrifuge, and resuspended in 5% formic acid 5% acetonitrile. Samples were analyzed by LCMSMS using an EASYnLC1000 in combination with an
Orbitrap Velos (both Thermofisher Scientific) using 60
min linear gradients from 100% solvent A (water with
0.1% formic acid) to 35% solvent B (acetonitrile with
0.1% formic acid) 65% solvent A (for details see, [64]).
Raw data were analyzed using MaxQuant software
1.5.3.8 [14] with the following parameters: variable modifications: replacement of methionine by AHA, acetylation at protein N-termini, oxidation at methionine;
fixed modification: propionamide at cysteine; maximum
number of modifications: 5; quantification multiplicity:
3plex SILAC; missed cleavage sites:2; MS mass tolerance
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first pass search: 20 ppm; MSMS mass tolerance: 0.5 Da.
Match between runs was activated and the database used
was Uniprot mouse (release date 22.07.2015) in combination with common contaminants.
Proteomics of neuronal cells

Differentiated NSC-34 cells were treated with 5 μg/ml
recombinant human CTRP3 protein for 6 h. Cells were
lysed in RIPA buffer with protease and phosphatase inhibitors and DNA was sheared by sonication. Proteins
were precipitated using ice-cold acetone and the pellet
was dissolved in 6 M urea/ 2 M thiourea. This was
followed by an in-solution reduction using 5 mM dithiothreitol (DTT), an alkylation using 40 mM iodoacetamide (IAA) and the digestion with endoproteinase Lys-C
and trypsin. Acidified peptide samples were purified
using styrenedivinylbenzene-reverse phase sulfonate
(SDB-RPS) Stage Tips [58]. An Easy nLC 1000 ultra-hig
performance liquid chromatography (UHPLC) coupled
to a QExactive Plus Hybrid Quadrupole-Orbitrap mass
spectrometer (Thermo Scientific) was used for proteomic analysis. Raw data were analyzed using the
Andromeda search engine (MaxQuant software 1.5.3.8)
[14]. Parameters in MaxQuant were set to default with
trypsin selected as protease for digestion. Additionally,
match-between runs and LFQ quantification algorithms
were enabled. A mouse database from Uniprot (16.06.17)
with contaminants was used for peptide and protein identification. Statistical analysis, GO annotations, t-tests and
data visualization were performed using the Perseus software [71] and the Instant Clue software [53].
SUnSET assay (SUrface SEnsing of translation)

To monitor the effect of CTRP3 on the protein synthesis
efficiency, we performed SUnSET assay [63]. In brief,
culture medium of differentiated NSC-34 cells was
treated with 5 μg/ml recombinant mouse CTRP3 protein
for either 2 or 6 h. 1 h prior protein collection 1 μM
puromycin was added to label proteins that are in the
middle of synthesis. To measure the protein synthesis efficiency, puromycin-labelled proteins/peptides were detected by Western blot analysis using anti-puromycin
antibody. Protein synthesis efficiency was compared with
non-treated control cells.
To measure protein synthesis in primary motor neurons, 3DIV motor neurons were treated with 5 μg/ml recombinant human CTRP3 for 2 h and proteins were
labelled with 1 μM puromycin for 30 min. After that,
neurons were fixed with 4% paraformaldehyde (PFA) for
20 min, and puromycin signals were visualized with antipuromycin antibody (modified from [44]). Images were
taken blindly with a light microscope (Zeiss) and analysed with Fiji.
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Axon outgrowth assay

25,000 motor neurons/cm2 were seeded on PDL-coated
cover-slips and grown for 3 days. Two days after plating,
motor neurons were treated with 5 μg/ml recombinant
human CTRP3 for 24 h, and cells were fixed with 4%
PFA for 20 min. Neuronal morphology was visualized
with anti-TAU antibody and motor neuron identity was
confirmed with anti-ChAT antibody. Images were taken
blindly with a light microscope (Zeiss) and analysed with
Fiji. The information about antibodies can be found in
Additional file 1: Table S2.
Image analysis

All images were acquired with a light microscope (Zeiss
Axio Imager.M2) equipped with an AxioCam MR
camera and an ApoTome.2 system (Institute of Human
Genetics, University of Cologne). Images were analyzed
with the ZEN (Zeiss) or Fiji. All image analyses were
performed blindly.
Statistical test and GO analysis

Statistical tests were performed by Prism (Graphpad)
and GO/pathway analysis was performed by g:Profiler
and Reactome (reactome.org).

Results
Systemic muscle secretome analysis: secretion of CTRP3 is
reduced in SMN-deficient muscle cells

We screened secreted proteins from control and SMNdeficient muscle cells with a combination of two metabolic labeling methods and mass spectrometry (MS). As
muscle cells need 5% of horse serum for differentiation
and horse serum contains numerous proteins, we
adapted Click-iT AHA (L-azidohomoalanine) method to
distinguish muscle secreted proteins from serum proteins in conditioned culture media. Additionally, we also
used SILAC (stable isotope labeling by amino acids in
cell culture) [54] to determine whether proteins are secreted from control cells or SMA cells. Immortalized H2Kb-tsA58 (H-2Kb) myoblasts were cultured and differentiated as previously described [49]. In brief, cells fused
and formed myotubes within 3 days in differentiation
medium (Fig. 1a). With siRNA technology and transient
transfection, we could successfully reduce SMN protein
levels to ~ 40% of control levels in 72 h (Fig. 1b). With
this optimized protocol, cells were cultured in 500 μM
AHA containing SILAC differentiation media, and the
medium of control cells (negative control siRNA, siCon)
was supplemented with intermediate isoforms of arginine and lysine (13C6-Arg, d4-Lys) and Smn KD (Smn
knockdown, siSmn) with heavy isoforms (13C6 15N4-Arg,
13
C6 15N2-Lys) for 72 h. Next, we collected media from
control and Smn KD muscle cells, enriched and isolated
newly synthesized proteins with Click-iT chemistry.
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Fig. 1 SMN-depleted muscle cells secrete reduced levels of CTRP3 protein. Quantitative secretome analysis of metabolically labelled SMN-depleted
muscle cells. a H-2Kb-tsA58 cells were differentiated to multinucleated myotubes within 3 to 5 days (10x, 20x). b Representative Western blots and
quantification showing knockdown efficiency. Negative control siRNA (Control) or siRNA against Smn (SmnKD) was transfected, and cells were
differentiated for 72 h. GAPDH was used as a loading control (n = 4). c Schematic drawing of quantitative secretome analysis. Simultaneous siRNA
transfection and combined pulsed labelling of differentiating H-2Kb-tsA58 muscle cells with azidohomoalanine (AHA) and stable isotope-labelled
amino acids. Newly synthesized proteins were isolated by click chemistry and analyzed by mass spectrometry. d Volcano plot of secretome
analysis; statistical significance (−log10, p-value) against fold change (FC, log2, Control/SmnKD). Normalized SILAC ratios of 4 replicates were used
to calculate the log2 ratio between SmnKD (heavy) and control (intermediate) conditions, and p-values were determined using an unpaired twosided t-test. Proteins with a p-value < 0.05 are highlighted in green/red and proteins with a FC > 50% are additionally labelled with name. e
Representative Western blots and quantification of C2C12 cells transfected with negative control siRNA (Control) or siRNA against Smn (SmnKD),
and differentiated for 5 days. ACTB was used as a loding control. f Representative Western blots and quantification of serum-free conditioned
media of control and Smn KD C2C12 cells, differentiated for 5 days. CTRP3 levels were normalized to the total protein amount (stainfree gel). Dot
graphs represent data from independent experiments and the bar graphs depict the mean ± s.d. Two-tailed unpaired student’s t-test was used to
determine statistical signaficance. ***p < 0.001; **p < 0.01

With this condition, we screened secreted proteomes
from control and Smn KD muscle cells with mass
spectrometry (Fig. 1c). Importantly, we have confirmed
that 72 h treatment of 500 μM AHA has neither an effect
on muscle cell differentiation nor the cell death
(Additional file 2: Figure S1). From 4 replicated experiments, we have detected 1739 proteins from whole
secretomes, and among them, levels of 25 proteins were
significantly altered by SMN deficiency (p-value < 0.05,
Fig. 1d, Table 1 and Additional file 3: Data S1). Pathway
analysis has revealed that muscle-secreted proteins regulate eukaryotic translation and SLIT/ROBO expression,
which are important for axon guidance and motor
neuron positioning in spinal cords [36, 43] (Additional
file 1: Table S3). Furthermore, we also performed pathway analysis of differentially secreted proteins in Smn
KD muscle cells. Interestingly, collagen metabolism and
the regulation of IGF (insulin like growth factor) pathway are significantly altered in Smn KD muscle secretomes (Additional file 1: Table S4). As collagen
metabolism is important for the function of extracellular
matrix at the neuromuscular junction [39, 62] and IGF
pathway has been implicated in SMA pathology [5, 70],
this finding substantiates the quality of our data.
We have also performed same experiments with
muscle cell samples. Notably, with ~ 40% of SMN levels,
only 30 proteins were significantly altered using the
same criteria for secretome analysis (Additional file 2:
Figure S2 and Additional file 1: Table S5). Consistent
with the secretome data, SMN deficient muscle cells also
showed altered protein levels linked to collagen metabolism, protein and RNA homeostasis and peroxisomal protein import (Additional file 1: Table S6).
Among 25 differentially secreted proteins, the most
significantly altered protein was C1QTNF3 (C1q/tumor
necrosis factor-related protein 3, also known as CTRP3,
Fig. 1d). We tested whether CTRP3 secretion is also
changed in another muscle cell line, C2C12. We

knocked down Smn with siRNA, differentiated cells and
measured secreted CTRP3 levels in conditioned media
by Western blot analysis. Indeed, with ~ 50% reduction
of SMN, CTRP3 secretion is reduced in Smn KD C2C12
cells (Fig. 1e and f). From these findings, we concluded
that proteins are differentially secreted from SMA
muscle cells and that CTRP3 is the most strongly changed secreted protein upon SMN depletion.

CTRP3 levels are reduced in tibialis anterior muscle tissues
and plasma of SMA mice

Next, we assessed CTRP3 levels in an SMA mouse
model [30]. We measured the levels of CTRP3 in three
different muscle tissues from postnatal day 7 (P7) WT
and SMA mice. Interestingly, CTRP3 levels were exceedingly reduced in tibialis anterior, while they were not
significantly changed in gastrocnemius and masseter
muscles (Fig. 2a-c). These data are in line with previous
reports suggesting that SMN deficiency influences gene
expression in muscle [8, 9] and tibialis anterior has been
reported as a vulnerable muscle tissue in the same SMA
mouse model used in this study [67]. Next, we checked
the localization of CTRP3 proteins in muscle tissues. In
gastrocnemius muscle of P7 mice, CTRP3 protein signal
was detected in muscle fibers as dot-like structures and
it seems enriched in the extracellular matrix (Fig. 2d and
Additional file 2: Figure S3). Furthermore, as CTRP3 is a
secreted molecule, we tested CTRP3 levels in blood
plasma from P7 WT and SMA mice and found that
blood plasma CTRP3 levels are significantly reduced in
SMA mice (Fig. 2e). In addition, as liver is the major
source of blood plasma proteins, we measured the levels
of CTRP3 in liver. CTRP3 levels in livers of P7 mice
seem unaltered by SMA (Additional file 2: Figure S4).
Taken together, we confirmed that CTRP3 levels were
reduced in tibialis anterior muscle and plasma of SMA
mice.
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Table 1 Differentially secreted proteins from control and Smn KD H-2Kb-BL6 muscle cells (p < 0.05)
Gene name

Protein name

# of unique peptides

P value

Fold change
SmnKD/Cont

GO/KEGG

Vapa

Vesicle-associated membrane protein-associated protein A

2

0.0028

4.903

Tight junction

Cxcl1

Fractalkine

3

0.0220

1.365

Chemokine signaling
exosome

Dpp2

Dipeptidyl peptidase 2

5

0.0063

1.286

exosome

Serpinh1

Serpin H1

15

0.0331

1.182

Timp1

Metalloproteinase inhibitor 1

6

0.0293

1.167

Alad

Delta-aminolevulinic acid dehydratase

7

0.0132

1.165

Col4a1

Arresten;Collagen alpha-1(IV) chain

33

0.0209

1.140

Extracellular matrix,
exosome

Lgals1

Galectin-1

8

0.0142

1.139

exosome

Serpine2

Glia-derived nexin

9

0.0386

1.109

exosome

Rcn1

Reticulocalbin-1

6

0.0138

1.101

Ca2+ binding

Msn

Moesin

23

0.0140

1.071

Actin cytoskeleton,
cell junction, exosome

Lgal3bp

Galectin-3-binding protein

5

0.0353

1.070

exosome

Lsyna1

Inositol-3-phosphate synthase 1

7

0.0411

0.920

Atp5j2

ATP synthase subunit f, mitochondrial

1

0.0414

0.914

ATP synthesis, oxidative
`phosphorylation

Tbl1xr1

F-box-like/WD repeat-containing protein
TBL1XR1

2

0.0346

0.907

Wnt pathway,

Actn2

Alpha-actinin-2

22

0.0364

0.885

Cell junction, actin
cytoskeleton

Xirp1

Xin actin-binding repeat-containing
protein 1

4

0.0295

0.871

Cell junction, actin
cytoskeleton

Uqcrc1

Cytochrome b-c1 complex subunit 1,
mitochondrial

7

0.0206

0.852

Oxidative phosphorylation,
Alzheimer’s, Parkinson’s,
Huntington diseases

Phb2

Prohibitin-2

7

0.0082

0.845

Ermp1

Endoplasmic reticulum metallopeptidase 1

2

0.0099

0.841

Col4a2

Canstatin; Collagen alpha-2(IV) chain

36

0.0454

0.655

Focal adhesion, exosome

Col5a2

Collagen alpha-2(V) chain

37

0.0008

0.592

Focal adhesion, exosome

C1qtnf3

Complement C1q tumor necrosis factorrelated protein 3

3

7.77E-0.5

0.455

Glucose homeostasis, exosome

Cp

Ceruloplasmin

2

0.0313

0.402

Cu-oxidase, exosome

Serpinc1

Antithrombin-III

5

0.0049

0.391

Complement and coagulation
cascades, endopeptidase
inhibitor, exosome

CTRP3 regulates protein synthesis in neurons

As secretion of CTRP3 is reduced in SMA muscles, we
further investigated the role of CTRP3 in motor neuron
physiology. Originally, CTRP3 has been described as an
adipokine, which is important for metabolism related
pathways in various tissues [78]. In brain, it plays a neuroprotective role after injury caused by intracerebral
hemorrhage [73]. Therefore, we first measured CTRP3
levels in brain and spinal cord of WT and SMA mice.
CTRP3 proteins were detected in both brain and spinal
cord from P7 WT and SMA mice, but the levels of
CTRP3 were reduced only in brain of SMA mice
(Additional file 2: Figure S5). Prior to analyzing

Exosome

downstream pathways, we optimized exogenous CTRP3
treatment in motor neurons. For optimization, we used
a motor neuron-like cell line, NSC-34 cells. NSC-34 cells
were differentiated 3 days with 50 μM retinoic acid (RA)
and treated with recombinant CTRP3 protein (Additional
file 2: Figure S6). We found that 5 μg/ml CTRP3 induces
changes in signaling pathways in NSC-34 cells. For further
experiments, we used 5 μg/ml as optimal condition.
To obtain a systemic view of CTRP3 function in neurons, we next profiled downstream pathways of CTRP3
by mass spectrometry. We differentiated NSC-34 cells
with RA for 3 days, treated them with 5 μg/ml CTRP3
for 6 h, and performed whole proteome analysis (Fig. 3a
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Fig. 2 CTRP3 levels are reduced in tibialis anterior muscle and blood plasma of SMA mice. Representative Western blots and quantification of
CTRP3 levels in SMA mice. a tibialis anterior (WT N = 6; SMA N = 5), b gastrocnemius (N = 5) and c masseter (N = 4) muscles of P7 WT and SMA
mice. ACTB was used as a loading control. d Immunofluorescence staining of an cross section of gastrocnemius muscle of a P7 WT mouse, using
anti-Laminin α2 (red), anti-CTRP3 (green) and DAPI (blue). Scale bars = 200 μm. e Representative Western blots and quantification of blood plasma
proteins isolated from P7 WT and SMA mice. CTRP3 levels were normalized to the total protein amount (stainfree gel) (N = 9). Dot graphs
represent data from independent experiments and the bar graphs depict the mean ± s.d. Two-tailed unpaired student’s t-test was used to
determine statistical signaficance. ** p < 0.01, n.s = not significant, p > 0.05

and Additional file 4: Data S2). From the profiling, 5653
proteins were detected, and 118 proteins were significantly altered (p < 0.05). However, levels of only 33 proteins were changed more than 25% by CTRP3 treatment.
Among them, the most upregulated protein was CKS2
(cyclin-dependent kinases regulatory subunit 2), and the
most downregulated protein was GHITM (growth hormone inducible transmembrane protein) (Fig. 3b and
Additional file 1: Table S7). As the number of altered
proteins with these criteria was too low, we used proteins with p < 0.1 for pathway analysis, which are 291
proteins. Thereby, we found that pathways associated
with protein synthesis including translation initiation,
elongation, ribosomes and insulin receptor recycling are
predominantly altered by CTRP3 treatment (Fig. 3c and
Additional file 1: Table S8). Interestingly, PTEN

expression was reduced about ~ 50% by CTRP3 treatment. As PTEN plays an important role in protein synthesis, we confirmed the PTEN levels in CTRP3 treated
NSC-34 cells by Western blot analysis (Fig. 3d and e).
This data validates quality of our mass spectrometry experiment. Next, we biochemically measured the protein
synthesis efficiency in CTRP3 treated NSC-34 cells with
SUnSET (SUrface SEnsing of Translation) method. In
brief, control and CTRP3 treated NSC-34 cells were incubated with a very low concentration of puromycin
(1 μM) for 1 h. Puromycin labelled the proteins synthesized during the given time, and these proteins could be
detected with an antibody against puromycin [63]. The
intensity of puromycin signal, in other word, the amount
of puromycin labelled newly synthesized proteins was
used as a measure for the protein synthesis rate. We
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Fig. 3 CTRP3 treatment stimulates protein synthesis in motor neuron-like NSC-34 cells. Downstream pathway analysis of CTRP3 in motor neuronlike NSC-34 cells. a Schematic drawing showing whole proteome analysis of differentiated NSC-34 cells. b Volcano plot of whole proteome
analysis; plotted statistical significance (−log10, p-value) against fold change (log2, CTRP3 treated/untreated). Cells were treated with 5 μg/ml
recombinant mouse CTRP3 (mCTRP3). Three independent samples were used for analysis. P-values were determined using an unpaired two-sided
t-test (n = 3). Proteins with p < 0.05 are highlighted in green (upregulated)/ red (downregulated) and proteins with p < 0.05 and FC > 50% are
additionally labelled with name. c Representative pathways changed by CTRP3 treatment. (proteins with p < 0.1 and pathways with p < 0.05, with
g:Profiler). d Representative Western blots for PTEN and e quantification of PTEN levels in CTRP3 treated differentiated NSC-34 cells, Two-tailed
unpaired student’s t-test was used to determine statistical signaficance, f Scheme of SUnSET assay. Differentiated NSC-34 cells were treated with
mCTRP3 for 2 or 6 h. Cells were incubated with 1 μM puromycin for 1 h before analysis. g SUnSET assay shows that CTRP3 increases protein
synthesis. h Dot plot bar graph summarizes SUnSET assay. SUnSET data were normalized to the total protein amount (ponceau). Each dot
represents an independent experiment and the bar graph represents mean ± s.d. (n = 16/10/10). One way ANOVA with Fisher’s LSD test was used
to determine statistical significance; * p < 0.05, ** p < 0.01
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treated CTRP3 to NSC-34 cells for 2 or 6 h and measured the protein synthesis efficiency (Fig. 3f). Indeed,
we confirmed that CTRP3 enhanced the protein synthesis rate in motor neuron like NSC-34 cells (Fig. 3g and
h).
CTRP3 enhances SMN and VEGF levels in motor neurons

While SMN is the most important protein for SMA, we
could not detect the SMN protein with mass spectrometric analysis of CTRP3 treated NSC-34 cells. Therefore, we measured SMN protein levels in motor neurons
after CTRP3 treatment. Additionally, it has been reported that CTRP3 regulates VEGF levels in brain [73]
and that extremely severely affected SMA patients and
mice show peripheral necrosis, which can be caused by
vascular defects [2, 30]. Therefore, we also independently measured VEGF protein levels in motor neurons
after CTRP3 treatment. We found that both SMN and
VEGF protein levels were elevated in WT and SMA
motor neurons upon CTRP3 treatment (Fig. 4a-f). It is
worthy to note that SMA neurons showed rather slow
increase in SMN protein levels after CTRP3 treatment
compared to WT ones. In WT motor neurons, CTRP3
treatment increases SMN levels in 6 h the most, but in
SMA motor neurons, SMN levels continue to increase
in 24 h (Fig. 4d and e). While we have already shown
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that CTRP3 increases the efficiency of protein synthesis
in neurons, mRNA levels were also measured by quantitative RT-PCR to clarify the molecular mechanism
underlying elevation of SMN and VEGF protein levels.
Indeed, neither of mRNA levels was altered (Additional
file 2: Figure S7). These results indicate that elevated
SMN and VEGF levels are due to the enhanced translation. From these findings, we concluded that CTRP3
enhances protein synthesis including SMN and VEGF in
neurons. Subsequently, we investigated the cellular mechanisms underlying CTRP3-mediated protein synthesis.
CTRP3 induced SMN protein synthesis is mTOR
dependent

While there are various mechanisms regulating protein synthesis, best known signaling pathways regulating mRNA translation in neurons are the PI3K/
mTOR and MAPK/ERK pathways. Of note, SMA neurons showed reduced mTOR activity and impaired
protein synthesis [37], as well as dysregulated MAPK/
ERK pathway [4]. Therefore, we tested whether
CTRP3 modulates these two pathways in NSC-34
cells as well as WT and SMA primary motor neurons.
First, we treated differentiated NSC-34 cells with
5 μg/ml CTRP3 and measured the phosphorylation
state of ERK and AKT as a marker of active MAPK/

Fig. 4 CTRP3 increases SMN and VEGF protein levels in primary WT and SMA motor neurons. Representative Western blots and quantification of
SMN and VEGF protein levels in CTRP3 treated motor neurons isolated from spinal cord of E13 mice. Embryonic motor neurons from WT (a-c)
and SMA (d-f) mice were cultured for 5 days in vitro (5DIV) and treated with 5 μg/ml mCTRP3 protein for 6 or 24 h. b, c, e and f Dot plot bar
graphs represent quantification of VEGF and SMN levels. ACTB was used as a loading control. Each dot represents independent experiment and
the bar graph represents mean ± s.d. (WT-SMN: n = 11, N = 5; WT-VEGF: n = 7, N = 3; SMA-SMN: n = 8; N = 3; SMA-VEGF: n = 11, N = 5, n: number of
independent experiments, N: number of independent neuron cultures) One way ANOVA with Fisher’s LSD test was used to determine statistical
significance; * p < 0.05, ** p < 0.01
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(See figure on previous page.)
Fig. 5 CTRP3 activates the PI3K/mTOR and MAPK/ERK pathway in motor neurons. a-e Representative Western blots and quantification of AKT and
ERK activity in NSC-34 cells treated with 5 μg/ml mCTRP3 for 5, 15, 30 or 60 min. Activity of PI3K and MAPK/ERK pathways were measured using
anti-p-ERK (Thr202/Tyr204) and anti-p-AKT (S473) antibodies. (n = 3) f-j WT and k-o SMA motor neurons treated with 5 μg/ml mCTRP3 for 5, 15, 30
or 60 min. Activity of PI3K/mTOR and MAPK/ERK pathways were measured using anti-p-S6K (Thr389) and anti-p-ERK (Thr202/Tyr204) antibodies.
ACTB was used as a loading control. g-j, l-o Dot plot bar graphs summarize the repeated experiments. Each dot represents an independent
experiment and bar graphs depict the mean ± s.d. (WT: n = 11 for p-ERK and n = 9 for p-S6K, SMA: n = 6 for p-ERK n = 8 for p-S6K) Kruskal Wallis
and Uncorrected Dunn’s test was used to determine statistical significance; ** p < 0.01 and * p < 0.05. p Differentiated NSC-34 cells were treated
with 100 nM of water-soluble mTOR inhibitor WYE-687 dihydrochloride and/or 5 μg/ml human CTRP3 (hCTRP3) for 2 h. q Representative Western
blots of NSC-34 cells with anti-p-S6 (Ser235/236), anti-S6 and anti-SMN antibodies show that elevated SMN levels by CTRP3 treatment were mTOR
dependent. ACTB was used as a loading control. r Dot plot bar graphs summarize the repeated experiments. Each dot represents an
independent experiment and bar graphs depict the mean ± s.d. Kruskal Wallis and Uncorrected Dunn’s test was used to determine statistical
significance; ** p < 0.01 and * p < 0.05

ERK and PI3K pathway respectively (Fig. 5a-e). We
found that the phosphorylation state of both ERK and
AKT were enhanced upon CTRP3 treatment. It is
noteworthy to mention that the activity of a direct
target of mTOR kinase, S6K (p70S6K) was extremely
low in NSC-34 cells, at least in our hands (data not
shown). Therefore, we could not reliably quantify
phosphorylation status of S6K in NSC-34 cells.
Next, we tested the effect of CTRP3 in 5DIV (days
in vitro) primary WT and SMA motor neurons. In primary motor neurons, we could measure mTOR activity
with phosphorylation status of S6K as well as ERK activity. In WT motor neurons, CTRP3 enhanced ERK activity moderately but significantly, while mTOR activity (pS6K) was not significantly altered (Fig. 5f-j). To our surprise, in SMA motor neurons, CTRP3 increased mTOR
activity enormously (Fig. 5k, n and o). As we have previously reported, SMA neurons often show extremely low
basal mTOR activity [37], therefore, fold induction of
S6K activity was more exaggerated in SMA motor neurons. While there was a trend of elevation, ERK activity
was not significantly altered by CTRP3 treatment in
SMA motor neurons (Fig. 5k, l and m).
mTOR kinases form two types of complexes based on
binding partners: mTORC1 and mTORC2. They play distinct roles in cellular processes [27]. It has been known
that mTORC1 mainly regulates protein synthesis, however, mTORC2 can also bind ribosomes directly [81].
mTORC1 phosphorylates p70S6K directly and mTORC2
phosphorylates AKT at S473. Therefore, these phosphorylation sites are often used as markers of mTORCs activity. To further characterize CTRP3-mediated mTOR
activation, we also measured the phosphorylation status of
AKT at S473 and found that CTRP3 does not activate
mTORC2 in WT primary motor neurons (Additional file
2: Figure S8). This data suggest that CTRP3 enhances
mTORC1 activity in primary motor neurons. Furthermore, we checked whether CTRP3 can regulate capdependent translation by phosphorylating 4E-BP1. Indeed,
phosphorylation of 4E-BP1 was elevated by CTRP3 in WT
motor neurons (Additional file 2: Figure S9). This finding

strongly suggests that CTRP3 enhances protein synthesis
via mTORC1, S6K and 4E-BP signaling cascade in motor
neurons.
Finally, to validate the role of the mTOR pathway in
CTRP3-induced SMN protein synthesis, we pharmacologically blocked mTOR activity and checked CTRP3induced SMN protein synthesis in NSC-34 cells (Fig. 5p).
Interestingly, in our hands, DMSO slightly but consistently increased the SMN protein level in motor neurons
(data not shown). Therefore, we used the water-soluble
mTOR inhibitor WYE-687 dihydrochloride to avoid
DMSO as a vehicle. Indeed, WYE-687 dihydrochloride
successfully diminished the CTRP3 induced SMN protein
synthesis as well as mTORC1 activity (Fig. 5q, r, and
Additional file 2: Figure S10). Additionally, we checked
whether ERK pathway also contribute to the CTRP3mediated SMN protein synthesis. To answer this question,
we treated 20 μM ERK inhibitor U0126 together with
CTRP3 to primary WT motor neurons, and checked
whether U0126 can block CTRP3-mediated SMN protein
synthesis. ERK inhibition does not affect CTRP3 mediated
SMN level elevation (Additional file 2: Figure S11). Taken
together, CTRP3 positively regulates protein synthesis
including SMN via the mTORC1 pathway in motor
neurons.
CTRP3 influences motor neuron growth and axonal local
protein synthesis

Finally, we explored the functional impact of CTRP3 in
motor neuron. Initially, we hypothesized that intrinsic
defects in SMA muscles affect the physiology of motor
neuron via a secreted-molecule related retrograde communication. In fact, we found that SMA muscle cells secrete reduced levels of CTRP3, a protein known for its
neurotrophic factor like functions. Therefore, we further
investigated the effects of CTRP3 in motor neurons.
First, as one of the best described phenotypes of SMA
motor neurons is impaired axonal growth, we tested
whether exogenous CTRP3 treatment can restore this
phenotype at an early stage of development. We treated
5 μg/ml CTRP3 to 2DIV motor neurons, and the length
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Fig. 6 CTRP3 stimulates axonal growth and protein synthesis of motor neurons. a Axon outgrowth assay with WT and SMA motor neurons
treated with 5 μg/ml hCTRP3 for 24 h (2DIV-3DIV). Representative images of motor neurons stained with anti-Tau (green), anti-ChAT (red) and
DAPI (blue). Scale bars: 20 μm. b Dot plot bar graph summarizes axon outgrowth analysis. Each dot represents the average axon length of 20–25
neurons in a coverslip. Bar graphs depict the mean ± s.d. (WT: n = 9, N = 3; SMA: n = 17, N = 4; n = number of coverslips, N = number of
independent cultures). Two way ANOVA with Sidak’s multiple comparison test was used to determine statistical significance; **p < 0.01, ****p <
0.0001. c Scheme of SUnSET assay to investigate the effect of CTRP3 on axonal protein synthesis. Motor neurons (3DIV) were treated with 5 μg/ml
hCTRP3 for 2 h and newly synthesized proteins were labelled with 1 μM puromycin for 30 min before analysis. Data are compared with nonCTRP3 treated cells. As a negative control, protein synthesis was blocked with 50 μM anisomycin for 1 h before analysis. d Representative images
of WT and SMA motor neurons immunologically stained with anti-puromycin antibody. Rainbow scale heatmap indicating the intensity of
SUnSET signals. e Dot plot bar graph represents the mean intensity of the SUnSET signal in soma of WT motor neurons. Each dot represents the
average value of 24–28 neurons from an independent culture and bar graphs depict the mean ± s.d. (Untreated n = 8/N = 8, CTRP3 treated n = 8/
N = 8, anisomycin treated n = 5/N = 5, n = number of coverslips, N = number of independent cultures, 25 neurons per coverslip). Ordinary one-way
ANOVA and Uncorrected Fisher’s LSD were used to determine statistical significance. ****p < 0.0001, f-g Quantification of the mean intensity of
the SUnSET signal in axons (per 20 μm). f SUnSET signal in axon (WT N = 8, SMA N = 8, N = number of independent cultures). Each dot represents
average data from one independent neuron culture. Therefore, data were only compared in the same culture with and without CTRP3 treatment.
Two-tailed paired student’s t-test was used to determine statistical significance, **p < 0.01. To compare WT and SMA, unpaired t-test was used to
determine statistical significance, and it was not significant. g Each dot represents a value from a neuron, WT untreated n = 204, WT CTRP3
treated n = 293, SMA untreated n = 200, SMA CTRP3 treated n = 200. Two way ANOVA with Sidak’s multiple comparison test was used to
determine statistical significance; *p < 0.05, **p < 0.01, h-i Quantification of the ratio of the SUnSET signal in axons (per 20 μm) compared to
average signal in soma. h Ratio between soma and axons were increased by CTRP3 treatment, WT N = 8, SMA N = 8. Each dot represents average
data from one independent neuron culture. Therefore, data were only compared in the same culture with and without CTRP3 treatment. Twotailed paired student’s t-test was used to determine statistical significance. ***p < 0.001 and **p < 0.01. To compare WT and SMA, unpaired t-test
was used to determine statistical significance. *p < 0.05. i Ratio between soma and axons in individual neurons, each dot represents a value from
a neuron, WT untreated n = 204, WT CTRP3 treated n = 293, SMA untreated n = 200, SMA CTRP3 treated n = 200. Two way ANOVA with Sidak’s
multiple comparison test was used to determine statistical significance; *p < 0.05, **p < 0.01, ***p < 0.001

of Tau-positive neurites was measured after 24 h. The
majority of 3DIV motor neurons show one dominant
Tau-positive neurite (Fig. 6a). We also used choline
acetyl transferase as a marker for motor neurons (Fig.
6a). We observed that 24 h of 5 μg/ml CTRP3 treatment
enhanced axonal outgrowth in WT and SMA motor
neurons (Fig. 6b). Second, we tested whether CTRP3 can
increase the local protein synthesis efficiency in the
axonal compartment. Previously, it has been reported
that SMA neurons show an impaired local translation
rate in actively growing axons [1, 37]. Therefore, we
tested whether exogenous CTRP3 can enhance local
translation rate in growing axons. We labelled newly
synthesized proteins in 3DIV motor neurons by
incubating the cells with a low puromycin concentration
(1 μM) for 30 min, visualized these proteins with antipuromycin antibody, and measured the protein synthesis
efficiency in the axonal compartment of WT and SMA
motor neurons. To assure our experimental design, we
used two negative controls. On the one hand, we treated
cells with 50 μM anisomycin, a protein synthesis blocker,
30 min prior puromycin incubation (Fig. 6c). On the
other hand, we stained untreated (without puromycin
incubation) neurons with puromycin antibody to check
background signals and could not detect any signals
(Additional file 2: Figure S12). In addition, 30 min of anisomycin treatment successfully reduced the protein synthesis in neurons and this could be measured by
SUnSET (Fig. 6d, e and Additional file 2: Figure S13).
With this optimized protocol, we measured the intensity

of SUnSET signals in a 20 μm length section in distal
axons. We always measured the most distal axons, adjacent to the growth cones. As 3DIV motor neurons are
usually 120–150 μm long (Fig. 6b), the data obtained
from the axonal area was usually 80–100 μm apart from
the neuronal soma. This was to avoid the signals from
proteins anterogradely trafficked from soma to axon.
This experiment revealed that CTRP3 enhances protein
synthesis in axonal compartment (Fig. 6d, f and g) and
that SUnSET signal is more than 10-fold higher in soma
compared to axon (Fig. 6h and i). Furthermore, while we
cannot fully explain the mechanism at the moment, we
found that the ratio of protein synthesis between soma
and axons is reduced in SMA motor neurons compared
to WT ones, and that this is enhanced by CTRP3 treatment (Fig. 6 h and i). As protein synthesis efficiency in
soma is already low in SMA neurons, these results suggest that protein synthesis is even more impaired in
SMA axons. Taken together, our findings imply that
there are additional mechanisms regulating protein synthesis in axons, and that this mechanism is dysregulated
in SMA and can be restored by CTRP3 treatment.

Discussion
The present study provides the first line of evidence that
muscles regulate neuronal protein synthesis via secretory
pathway, and that this mechanism is dysregulated in a
neuromuscular disease, spinal muscular atrophy. While
it has been debated whether axonal local protein synthesis can take place in vivo or fully mature neurons,
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growing evidence supports that proteins can be synthesized in axons and that protein synthesis rate can be regulated by external signals such as neurotrophic factors
and axon guidance molecules (recently reviewed in [13]).
However, it remained elusive how protein synthesis is
regulated at the neuromuscular junctions, the synapses
between motor neuronal axons and muscle fibers. In this
study, we report that muscles can regulate axonal local
translation via a secreted molecule, CTRP3, and that this
mechanism is mTOR dependent. Impaired axonal local
protein synthesis has been observed in another neuromuscular disease, ALS [44]. As lower motor neurons
have extremely long axons, we can postulate that sufficient axonal protein synthesis is particularly important
for proper function of lower motor neurons, and that
their dysfunction can cause motor neuron diseases such
as ALS and SMA. However, the molecular mechanisms
regulating axonal protein synthesis in lower motor neurons needs further investigation.
Most importantly, we found that CTRP3 increases the
protein levels of SMN and VEGF in motor neurons.
Needless to say, SMN is the disease-causing protein in
SMA and the level of SMN protein highly correlates
with severity and progress of the disease. In severe cases
of type I SMA patients and severe SMA mice, defects in
the vascular system are evident and it might be causative
for the distal necrosis [2, 30]. Therefore, we can speculate that restoring CTRP3 levels in SMA would increase
the levels of SMN and VEGF, and thereby attenuate
SMA disease progression.
Muscle has been recognized as an important endocrine organ as it secretes various signaling molecules in
response to physical activity. For example, it is known
that muscle contraction elevates the secretion of growth
factors such as IGF-1 and FGF-2, which stimulate bone
formation [26]. In other context, muscle can release cytokines such as IL-6, IL-8 and IL-15 in response to physical activity [56]. Until now, as muscles and bone are
physically directly connected, research of the muscle
secretome has been focused on the function in bone
physiology. Here, we provide the first evidence showing
the influence of muscle on physiology of neurons.
Low serum CTRP3 levels are linked to metabolic
disorders such as type 2 diabetic mellitus and obesity
[46, 77]. Interestingly, SMA patients and mouse models
show dysfunctional glucose metabolism and defects in
the pancreas [6, 16]. Based on these findings we can
speculate that reduced serum CTRP3 levels can be due
to metabolic dysfunction observed in SMA. However, it
is important to note that our initial screening was performed in vitro cell culture system, which is influenced
by neither other organs nor glucose supply. Therefore,
this data led us to conclude that reduced secretion of
CTRP3 is rather due to intrinsic defects in SMN
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deficient muscle cells. While the role of CTRP3 has been
actively investigated in liver and kidney [48, 57] and genetically modified CTRP3 levels in mouse models show
obvious effects on liver function [69, 76], the role of
CTRP3 in neuromuscular systems has not been investigated so far. It will be important to check the neuromuscular system in genetically modified CTRP3 mouse
models. Taken together, our data strongly implies molecular interaction between the neuromuscular system
and glucose metabolism at the organismal level.
It is hitherto unknown how CTRP3 works on intracellular
signal transduction pathways in neurons. It has been reported that CTRP3 binds to the lysosomal proteins, LAMP1
and LIMP II in a hepatoma cell line [42]. While LIMP II is
located in the cell membrane, LAMP1 is not much located
on the cell surface [65]. At the moment, the nature of
CTRP3 action in neuronal cell signaling remains unclear.
However, these data implies that CTRP3 may be taken up
by cells via endocytosis and processed by endo-lysosomal
pathway similar to BDNF and adiponectins [10, 19]. As the
endocytosis pathway is impaired in SMA cells [29, 32, 60],
this hypothesis could explain why the effect of CTRP3 on
mTOR activation was slower in SMA motor neurons than
in WT ones (Fig. 5). Furthermore, SMN protein levels were
highest after 6 h treatment in WT motor neurons, but they
were increased till 24 h after treatment in SMA ones (Fig.
4). In addition to that, receptor mediated signal transduction pathways are often regulated by a clathrin-dependent
endocytosis pathway [19], which is impaired in SMA [60].
Together, these data strongly suggest that SMA motor
neurons show altered kinetics in CTRP3 down-stream pathways. The molecular mechanism of CTRP3 signal transduction needs to be further characterized.
While our presented work here is focused on one
protein CTRP3, there are other interesting candidate proteins whose secretion is altered in SMA muscle cells.
Among them, one good example is VAPA (vesicle-associated membrane protein, associated protein A). Interestingly, mutations in the VAPA homolog VAPB (vesicleassociated membrane protein, associated protein B) have
been reported as causative mutations in amyotrophic lateral sclerosis and late-onset spinal muscular atrophy [52].
VAPA and VAPB can form heterodimers and play an important role in vesicle trafficking together with VAMP-1
and -2 at the synaptic site [74]. As vesicular trafficking is
impaired in SMA [17, 29] and VAPA secretion is elevated
in SMA muscles, the role of VAPA in SMA can be interesting for investigation. Further interesting candidates are
collagens as COL4A1, COL4A2 and COL5A2 were differentially secreted by SMA muscles (Table 1). Collagens are
a major component of the extracellular matrix- essential
for intercellular connections and signal transduction- and
required for the structural and functional integrity of the
NMJ [12]. Interestingly, mutations in Col4a1 and Col4a2
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can cause neuromuscular dysfunction, vascular defects,
myopathies and neurological disorders including epilepsy
and cortical malformations [11, 33, 38, 80]. As both SMA
and Col4a1-related disorders clearly share a common feature, neuromuscular dysfunction and vascular abnormality, collagens are a highly interesting topic for future
studies to identify a new neuro-pathogenic pathway.

Conclusion
Here we present a novel mechanism regulating neuronal
local protein synthesis. We found that secretion of
CTRP3 is reduced in SMA muscle cell lines, its expression is reduced in vulnerable tibialis muscle tissues, and
blood plasma of SMA mice. Furthermore, CTRP3 regulates global/axonal protein synthesis and axonal growth
in motor neurons. Importantly, CTRP3 enhances protein
synthesis of SMN via activating mTOR pathway. Taken
together, this is the first report showing that muscle regulates neuronal protein synthesis via the secretory pathway and that this process is dysregulated in the genetic
neuromuscular disease, SMA. These findings revealed a
new layer of neuro- pathogenic mechanism underlying
SMA and further suggest muscle as a therapeutic target
tissue in neuromuscular diseases.
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